AP: Vaccine storage issues could leave 3B people without access (Hinnant/Mednick, 10/25).

AP: Brazil approves import of Chinese shot that Bolsonaro nixed (Sciaudone, 10/23).

Bloomberg: Venezuela’s Maduro Presents ‘Molecule’ That Inhibits Covid-19 (Zerpa, 10/25).

Bloomberg: Johnson & Johnson, AstraZeneca Trials to Resume, Rejoining Vaccine Race (Griffin et al., 10/24).

DW: Coronavirus: Germany warns against ‘vaccine nationalism’ (Connor, 10/25).

Financial Times: Oxford Covid vaccine trials offer hope for elderly (Neville et al., 10/26).

Financial Times: AstraZeneca and J&J get go-ahead to resume Covid-19 vaccine trials (Kuchler/Stacey, 10/23).

The Guardian: Rush for results could lead to inferior Covid vaccine, say scientists (McKie, 10/25).

New York Times: The Trump Administration Shut a Vaccine Safety Office Last Year. What’s the Plan Now? (Zimmer, 10/23).

Reuters: As it hits 1 million coronavirus cases, Colombia prepares for vaccine (Cobb, 10/24).

Reuters: WHO says it will have advice on Remdesivir in 3-4 weeks (10/23).

Reuters: WHO: Nations mulling Gilead’s COVID drug should consider trial flop, too (Nebehay/Miller, 10/23).

Reuters: Mexico will not follow FDA in approving Gilead’s COVID-19 drug (Angulo/Solomon, 10/23).

STAT: FDA shows signs of cold feet over emergency authorization of Covid-19 vaccines (Branswell, 10/23).

STAT: Why the approval of remdesivir to treat Covid-19 obscures bigger scientific failures (Herper/Feuerstein, 10/23).

Wall Street Journal: To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Competitors (Walker, 10/24).